Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous EBV-transformed B lymphoblastoid-tumor fusion cell vaccine
- Development stage
- Phase 1
- Lead developer
- Penn State Health
- Modality
- Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intradermal
01
Overview
A cell-based therapeutic cancer vaccine composed of a patient's own (autologous) tumor cells fused with their own Epstein-Barr virus (EBV)-transformed B-lymphoblastoid cells. The resulting hybrid cells combine the antigen-presenting capabilities of EBV-transformed B-lymphoblastoid cells with the full spectrum of tumor-associated antigens from the patient’s tumor. Upon administration, this vaccine is designed to stimulate a robust immune response—particularly T-cell mediated immunity—against the patient’s cancer by presenting both viral and tumor antigens to the immune system, thereby enhancing recognition and destruction of malignant cells[7]. This approach leverages both cellular immunotherapy and personalized medicine principles.
- Other names
- autologous Epstein-Barr virus-transformed B lymphoblastoid-tumor fusion cell vaccine
02
Targets
EBV-TCR (T-cell receptor recognizing tumor/EBV peptide–MHC class I complexes)T-cell receptor recognizing tumor/EBV peptide–MHC class II complexesMHC I (MHC class I})MHC II (Major histocompatibility complex class II receptor)
Beyond the preview
Go deeper on autologous EBV-transformed B lymphoblastoid-tumor fusion cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous EBV-transformed B lymphoblastoid-tumor fusion cell vaccine.